External Costs. 13.2.1 The Agency is entitled to separate payment of external costs, including necessary services, licences, products etc. from external suppliers.
External Costs. You are responsible for any claims, fees, fines, penalties and other liability incurred by us or others caused by your use of the Services.
External Costs. “External Costs” shall include [*] to be used solely (or if applicable to other uses, then a fair allocation of such costs) in the conduct of the Research Program or NP201 Research Collaboration; provided, however, that Merck’s approval shall be obtained in writing in advance for such External Costs that are in excess of [*] for any such [*]; provided, further, that Merck shall not be responsible for [*]. For clarity, any External Costs that are: (i) approved by Merck under this Section 4.2.4, shall be included in the Research Funding Budget and shall, accordingly, be subject to, and count against, the Research Funding Cap; or (ii) not approved by Merck under this Section 4.2.4 (as and to the extent such approval is necessary), shall not be included in the Research Funding Budget, shall not count against the Research Funding Cap and NGM shall be solely responsible for any such costs.
External Costs. Xxxxxxx will charge for all bought in goods and services related to projects undertaken for Clients. Xxxxxxx will only incur and invoice external costs covered by an approved estimate or quotation. All invoices from external suppliers will be supported by documented proof of expense. Charges for design services to be provided by Xxxxxxx, will be set out in the written estimate or quotation that is provided to the Client. On receipt of the Client’s signed acceptance of this estimate or quotation, indicating acceptance of the Terms and Conditions, the Client agrees to pay all incurred fees, commissions and external costs up to the sum identified in the estimate or quotation. Payment Xxxxxxx may undertake interim invoicing throughout the duration of projects. Xxxxxxx will only invoice for fees, commission and external costs completed at the date of invoice. For final invoicing, a final invoice will be raised and issued to the Client. Accounts which remain outstanding for 30 days after the date of invoice, will incur an extra charge of 4% over bank base rate per month, of the outstanding amount. Payments may be made by cash, cheque, or BACS. Payment is preferred in Pounds Sterling, Euro or US Dollar. Publication and/or release of any work undertaken by Xxxxxxx on behalf of the Client, may not take place before cleared funds have been received or without written consent from Xxxxxxx. Returned cheques will incur an additional fee of £50 per returned cheque. Xxxxxxx reserves the right to con- sider an account to be in default in the event of a returned cheque. Default on Payment An account shall be considered default if it remains unpaid for 30 days from the date of invoice, or following a returned cheque. Xxxxxxx shall be considered entitled to remove Xxxxxxx’ and/or the Client’s material from any and all computer systems, until the amount due has been fully paid. This includes any and all unpaid monies due for services, including, but not limited to, hosting, domain registration, search engine submission, design and maintenance, sub-contractors, printers, photographers and libraries. Removal of such materials does not relieve the Client of its obligation to pay the due amount. Clients whose accounts become default agree to pay Xxxxxxx reasonable legal expenses and third party collection agency fees in the enforcement of these Terms and Conditions. Copyrights and Trademarks By supplying text, images and other data to Xxxxxxx for inclusion in print, website or ot...
External Costs. Pursuant to Section 76.922 of the FCC’s regulations, as such regulations may hereinafter be from time to time amended, “External Costs” shall mean costs of Licensee in the categories enumerated in such regulations, including, but not necessarily limited to, the following categories: (a) state and local taxes applicable to the provision of Cable Television Service; (b) franchise fees; (c) costs of compliance with franchise requirements, including costs of PEG access channels as required by the franchise authority; (d) retransmission consent fees; and (e) programming costs. Permitted per channel charges for regulated programming services may be adjusted to reflect changes in External Costs. Other costs may also be deemed External Costs in accordance with applicable law. As permitted by law, all External Costs, including those under this License, will be added onto the applicable rates, fees and charges of services and equipment paid by Licensee’s subscribers in Town.
External Costs. Seller shall not be required to expend more than an aggregate of Two Hundred Thousand Dollars ($200,000) on External Costs for the Project in any Contract Year or a total of One Million Six Hundred Fifty Thousand Dollars ($1,650,000) in the aggregate during the Term (collectively the “External Costs Requirement”). In the event Seller expects its External Costs may exceed the External Cost Requirement, Seller shall provide Notice to Buyer with an estimate of the External Costs Seller expects to incur. Buyer may, but is under no obligation to, within thirty (30) days of the delivery of such Notice with the estimate, provide Seller Notice of Buyer’s agreement to reimburse Seller for such costs, and thereafter Seller shall incur the External Costs in excess of the External Cost Requirement and invoice Buyer for such External Costs pursuant to Section 6.1. Seller shall have no obligation, and shall be free from liability under this Agreement if it fails, to take any action that causes, or would cause, Seller to incur External Costs in excess of the External Costs Obligation unless and until Seller receives Notice from Buyer within the thirty (30) day time period set forth above pursuant to which Buyer agrees to reimburse Seller for any External Costs incurred in excess of the External Costs Requirement.
External Costs. Each of ARQULE and DS shall be solely responsible for the payment of all Third Party research activity costs (“Third Party Costs”), including, without limitation, contract research organizations, contract personnel and consultant costs it incurs to meet its obligations under an Annual Research Plan; provided that if the external costs incurred by ARQULE for selectivity screening for any DS Target exceed * Dollars ($*) or the total amount required to be expended for selectivity screening by ARQULE exceeds * Dollars ($*), then ARQULE will notify DS and the Parties shall discuss the plan for any additional selectivity screening; provided that ARQULE shall not be required to perform any further selectivity screening.
External Costs. Contract Manufacturing and Performance of Clinical Trials The external costs associated with the Phase I clinical development of a single protein candidate is estimated to be approximately £[**]. A break down of the estimated external costs is given below. Function Process / Task Cost (£) Molecular Biology [**] [**] Total Molecular Biology [**] Product development [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] Total product Development [**] Analytical [**] [**] [**] [**] [**] [**] [**] [**] Total Analytical [**] Pre-clinical [**] [**] [**] [**] Total Pre-Clinical [**] Clinical testing [**] [**] [**] [**] Total clinical Testing [**] Clinical [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] Total Clinical [**] Schedule 1 Appendix 2 16 Function Process / Task Cost (£) Quality [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] Total Quality [**] Regulatory [**] [**] Total Regulatory [**] Total Other Costs [**] [**] Total Direct Project Cost [**] Schedule 1 Appendix 2 17 Schedule 1 Appendix 3 Later Stage Clinical Development Plan General Principles Following the completion of the Phase I activities for a Clinical Candidate, Sanofi will assume the main responsibility for subsequent Development, including later stage clinical trials (Phase II, Phase III and Phase IV or other post-marketing studies) together with the corresponding regulatory applications. Sanofi have considerable expertise and experience in the development of paediatric and meningococcal vaccines, with marketed polysaccharide vaccines Mengivac® (A + C) and Menomune® (A/C/W/Y) and marketed polysaccharide conjugate vaccine Menactra® (A/C/W/Y). The Parties intend that Sanofi will use this expertise to benefit the Development of a serogroup B vaccine Product and will proceed with Phase II and later stage clinical Development in the most appropriate and time efficient manner. Whilst it is not possible at the current stage of development to be definitive in the Later Stage Clinical Development Plan, the following represents the current view of the probable Later Stage Clinical Development Plan. This plan will be subject to periodic review by the Steering Committee (SC) and a more definitive Later Stage Clinical Development Plan will be agreed by the SC ahead of implementation of the Transition Plan for the relevant Clinical Candidate. For clarity, it is anticipated that the Later Stage Clinical Development Plan will include the Phase II and Phase III clinical s...
External Costs. Details of the breakdown external costs of the monotherapy clinical programme are also detailed in Schedule A. The total amount estimated is [***] [***]
External Costs. Should the Supplier deem it necessary to incur any of the following costs that will be for the Customer’s account, the Supplier must receive permission in writing from the Customer before incurring the relevant costs:-
